Sign up to save your podcasts
Or
Share Alzheimer's Disease and Gantenerumab: Trial Results and Future Directions
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Alzheimer's Disease and Gantenerumab: Trial Results and Future Directions
We delve into the results of the GRADUATE I and II trials, examining the impact of Gantenerumab, a human monoclonal antibody, on early Alzheimer's disease. We explore how its efficacy in reducing amyloid plaques failed to significantly alter the course of cognitive decline, while also discussing potential implications for future Alzheimer's disease treatments. Original article here.
ABOUT THE STATE OF HEALTH
The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit stateofhealth.care
FOLLOW US
View all episodes
By Medzcool
5
33 ratings
We delve into the results of the GRADUATE I and II trials, examining the impact of Gantenerumab, a human monoclonal antibody, on early Alzheimer's disease. We explore how its efficacy in reducing amyloid plaques failed to significantly alter the course of cognitive decline, while also discussing potential implications for future Alzheimer's disease treatments. Original article here.
ABOUT THE STATE OF HEALTH
The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit stateofhealth.care
FOLLOW US